The article highlights that 13 pharmaceutical companies have joined forces with academic institutions under the umbrella of the joint industry and EU-funded Innovative Medicines Initiative IMI on the “eTox” project. By sharing data on compounds they have tested in previous years, they are developing computer models to predict a drug’s toxicity, or how damaging it would be on a human, based on its chemical structure.
“There is a strong spirit of co-operation through public-private partnerships,” says Patrick Wier, GlaxoSmithKline’s vice-president for clinical safety. “Everyone appreciates the complexity of drug safety and recognises that we need to work together.”
eTOX project is coordinated by the GRIB.